<DOC>
	<DOCNO>NCT00227734</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , capecitabine oxaliplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Cetuximab may also stop growth tumor cell block enzymes need cell growth . It yet know whether give capecitabine oxaliplatin together cetuximab effective capecitabine oxaliplatin treat colorectal cancer . PURPOSE : This randomized phase II trial study well give capecitabine oxaliplatin together cetuximab work compare capecitabine oxaliplatin treating patient metastatic colorectal cancer remove surgery .</brief_summary>
	<brief_title>Capecitabine Oxaliplatin With Without Cetuximab Treating Patients With Metastatic Colorectal Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy capecitabine oxaliplatin v without cetuximab patient epidermal growth factor receptor-positive metastatic unresectable colorectal cancer . - Compare objective response ( complete partial response ) patient treat regimen . Secondary - Compare safety regimens patient . - Compare clinical benefit ( complete response , partial response , stable disease least 18 week ) patient treat regimen . - Compare overall survival , time progression , time treatment failure patient treat regimen . OUTLINE : This multicenter , randomize study . Patients stratify accord performance status ( 0 vs 1 ) , type metastasis ( synchronous vs metachronous ) , prior adjuvant chemotherapy ( yes v ) , participate center . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral capecitabine twice daily day 1-15 oxaliplatin IV 2 hour day 1 . - Arm II : Patients receive capecitabine oxaliplatin arm I cetuximab IV 1-2 hour day 1 8 . In arm , course repeat every 3 week 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 1 year every 6 month thereafter . PROJECTED ACCRUAL : A total 74 patient ( 37 per treatment arm ) accrue study within 1.5 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm metastatic colorectal cancer Unresectable disease Primary tumor metastasis must epidermal growth factor receptorpositive immunohistochemistry Measurable disease , define ≥ 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10 mm CT scan Measurable lesion must previously irradiate area No prior current CNS metastases PATIENT CHARACTERISTICS : Age 18 Performance status WHO 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin normal Renal Creatinine clearance &gt; 50 ml/min Cardiovascular No New York Heart Association class III IV congestive heart failure No symptomatic coronary artery disease No uncontrolled cardiac arrhythmia No myocardial infarction within past 12 month No significant cardiac disease Other Not pregnant nursing Fertile patient must use effective contraception 12 month study participation Negative pregnancy test No peripheral neuropathy origin &gt; grade 1 ( e.g. , alcohol diabetes ) No nausea , vomit , malabsorption syndrome would preclude ingestion absorption oral medication No severe reaction attribute fluoropyrimidine therapy No known hypersensitivity fluorouracil component trial drug No know dihydropyrimidine dehydrogenase deficiency No medical condition ( e.g. , uncontrolled diabetes active autoimmune disease ) , geographical situation , psychiatric disorder would preclude study compliance No malignancy within past 5 year except adequately treat carcinoma situ cervix localize nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy advanced metastatic cancer At least 6 month since prior adjuvant chemotherapy Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other At least 30 day since prior experimental drug No concurrent experimental drug No concurrent drug contraindicate use trial drug No concurrent anticancer therapy No concurrent sorivudine chemicallyrelated analogue ( e.g. , lamivudine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>